Authors
Latest:
Dr. Colin Weekes on Molecular Phenotyping in Pancreatic CancerColin Weekes, MD, PhD, associate professor, Department of Medicine and Medical Oncology, University of Colorado, on molecular phenotyping in pancreatic cancer patients.
Latest:
Ibrutinib Plus Venetoclax Is a Potential Second-line Regimen in MCLConstantine S. Tam, MD, discusses how ibrutinib plus venetoclax regimen from the SYMPATICO 2938 trial may fit in the relapsed/refractory mantle cell lymphoma setting.
Latest:
Recommendations for Treating Central Nervous System CancersIn season 4, episode 10 of Targeted Talks, Craig Horbinski, MD, PhD, reviews the clinical practice guidelines for central nervous system cancers.
Latest:
The Rationale for the Administering the Seviprotimut-L Vaccine to Patients with MelanomaCraig L. Slingluff, MD, explains the rationale behind part B1 of the MAVIS study , which is investigating the use of the Seviprotimut-L vaccine in melanoma.
Latest:
The Mechanism of Action of IbrutinibCraig L. Tendler, MD, discusses the mechanism of action of ibrutinib in various tumor types.
Latest:
Targeted Therapies for Patients With Ovarian Cancer Who Have BRCA-Mutated TumorsCristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses targeted therapies for <em>BRCA</em>1/2-mutated tumors.
Latest:
Results for the Combination of Selinexor and Daratumumab in Multiple MyelomaCristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting.
Latest:
New Targeted Therapy in Acute Lymphocytic Leukemia: A Review of Blinatumomab in Relapsed/Refractory Acute Lymphocytic LeukemiaAcute lymphoblastic leukemia (ALL) is a relatively rare malignancy in adults, with an estimated 6250 new cases and 1450 deaths expected in the United States in 2015. Although most patients achieve complete remission with conventional combination chemotherapy regimens, at least two-thirds of high-risk patients relapse.2 While overall survival for children has significantly improved in the last 30 years, newly diagnosed adults continue to have a poor 5-year OS rate, approximating 35%, depending on age and risk factors.
Latest:
Challenges With Patient Selection for Extended Adjuvant Endocrine Therapy in Breast CancerCynthia X. Ma, MD, PhD discusses the challenges with understanding treatment duration for adjuvant endocrine therapy in patients with breast cancer.
Latest:
NSCLC: Factors in Selecting 2L Therapy After Progression on 1L ALK TKIExpert perspectives on factors that aid in the selection of optimal therapy for patients with relapsed/refractory ALK+ non–small cell lung cancer.
Latest:
Immune Checkpoint Inhibitors Show Promise in Glioblastoma TreatmentAn emerging class of immune checkpoint blockade drugs has produced impressive benefits for patients in many solid tumor types. The class' success hints that these drugs ay be successful against central nervous system tumors as well, including glioblastoma.
Latest:
Dr. Danae Delivanis on Pembrolizumab and Nivolumab in Metastatic MelanomaDanae Delivanis, MD, endocrinologist, Mayo Clinic, on the use of pembrolizumab and nivolumab in the treatment of metastatic melanoma.
Latest:
Is It Time to Bring Back the French American British Classification System?Learning more about monocytic resistance to venetoclax is a new direction toward improving outcomes for patients with acute myeloid leukemia.
Latest:
Roundtable Discussion: Catenacci Compares Frontline Treatment for Patients With Gastric CancerThe treatment landscape for gastric cancer is evolving. The use of biomarkers and implementation of testing to improve outcome later on in the course of treatment are being more important.
Latest:
Expert Discusses When to Perform PSMA PET Imaging for Metastatic CRPCDaniel J. George, MD, discusses why he considers using prostate-specific membrane antigen imaging early in treatment of patients with castration-resistant prostate cancer.
Latest:
The Challenges of GVHD in Patients with LymphomaDaniel H. Fowler, MD, discusses the challenges of graph-versus-host-disease (GVHD) in patients with high-risk lymphoma.
Latest:
How T-rapa Cells WorkDaniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes how T-rapa cells work.
Latest:
Dr. Daniel Hamstra on the Benefits of Shorter Radiation Therapy Sessions for Prostate Cancer​Daniel Hamstra, MD, PhD, radiation oncologist, Texas Center for Proton Therapy, Texas Oncology, discusses the benefits of shorter radiotherapy treatment sessions for patients with prostate cancer.
Latest:
Overview of 4 FDA Approvals in Acute Myeloid LeukemiaDaniel J. DeAngelo, MD, PhD, associate professor at the Harvard School of Medicine and a member of the Adult Leukemia Program at Dana-Farber Cancer Institute, highlighted the 4 FDA approvals in the last year for the treatment of patients with acute myeloid leukemia.
Latest:
Clinical Pearls for Community Oncologists Treating Prostate CancerDaniel J. George, MD, offers closing thoughts and advice to community oncologists who treat patients with prostate cancer.
Latest:
Dr. Daniel J. Haraf on a Less Toxic Treatment for Patients With Head and Neck CancerHaraf says historically, medical professionals have treated patients with radiation therapy "from their eyebrows to their collarbones." This approach, while effective, has resulted in an abundance of toxicities.
Latest:
How Cabozantinib is Being Used in Practice for Patients With RCCDaniel James George, MD, professor of Medicine, professor in Surgery, Duke University School of Medicine, discusses how cabozantinib (Cabometyx) is currently being used in practice for patients with renal cell carcinoma (RCC).
Latest:
Targeting Oncogenic Driver Mutations for Cancer TherapyThe dependence of cancer cells on the continued activity of specific oncogenes for proliferation and survival can be explored for drug development.
Latest:
TITAN Trial Finds Survival Benefit for Apalutamide in mCSPCDaniel P. Petrylak, MD, discusses the design and results of the TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.
Latest:
Petrylak Reviews Results From KEYNOTE-921 in mCRPCDaniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.
Latest:
Dr. Oh Discusses myPlan Genetic Testing in Patients With Lung CancerDaniel S. Oh, MD, assistant professor of surgery, University of Southern California, Keck School of Medicine, discusses myPlan genetic testing in patients with lung cancer.
